Switch theme
Sign up to access all valuation multiples
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
1997
19
Last FY Revenue $2.0M
Last FY EBITDA -$20.7M
$21.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Valerio Therapeutics achieved revenue of $2.0M and an EBITDA of -$20.7M.
Valerio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Valerio Therapeutics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $2.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $1.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 70% | XXX | XXX | XXX |
| EBITDA | XXX | -$20.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1025% | XXX | XXX | XXX |
| EBIT | XXX | -$21.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1058% | XXX | XXX | XXX |
| Net Profit | XXX | -$22.9M | XXX | XXX | XXX |
| Net Margin | XXX | -1130% | XXX | XXX | XXX |
| Net Debt | XXX | $1.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Valerio Therapeutics's stock price is EUR 0 (or $0).
Valerio Therapeutics has current market cap of EUR 10.2M (or $11.4M), and EV of EUR 19.4M (or $21.8M).
See Valerio Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21.8M | $11.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Valerio Therapeutics has market cap of $11.4M and EV of $21.8M.
Valerio Therapeutics's trades at 10.8x EV/Revenue multiple, and -1.1x EV/EBITDA.
Equity research analysts estimate Valerio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Valerio Therapeutics's P/E ratio is not available.
See valuation multiples for Valerio Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.4M | XXX | $11.4M | XXX | XXX | XXX |
| EV (current) | $21.8M | XXX | $21.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialValerio Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.2M for the same period.
Valerio Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Valerio Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Valerio Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1025% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 538% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1129% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valerio Therapeutics acquired XXX companies to date.
Last acquisition by Valerio Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Valerio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Valerio Therapeutics founded? | Valerio Therapeutics was founded in 1997. |
| Where is Valerio Therapeutics headquartered? | Valerio Therapeutics is headquartered in France. |
| How many employees does Valerio Therapeutics have? | As of today, Valerio Therapeutics has 19 employees. |
| Is Valerio Therapeutics publicy listed? | Yes, Valerio Therapeutics is a public company listed on PAR. |
| What is the stock symbol of Valerio Therapeutics? | Valerio Therapeutics trades under ALVIO ticker. |
| When did Valerio Therapeutics go public? | Valerio Therapeutics went public in 2005. |
| Who are competitors of Valerio Therapeutics? | Similar companies to Valerio Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Valerio Therapeutics? | Valerio Therapeutics's current market cap is $11.4M |
| Is Valerio Therapeutics profitable? | Yes, Valerio Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
